177 related articles for article (PubMed ID: 18488157)
1. Thirty patients with primary plasma cell leukemia: a single center experience.
Colović M; Janković G; Suvajdzić N; Milić N; Dordević V; Janković S
Med Oncol; 2008; 25(2):154-60. PubMed ID: 18488157
[TBL] [Abstract][Full Text] [Related]
2. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
García-Sanz R; Orfão A; González M; Tabernero MD; Bladé J; Moro MJ; Fernández-Calvo J; Sanz MA; Pérez-Simón JA; Rasillo A; Miguel JF
Blood; 1999 Feb; 93(3):1032-7. PubMed ID: 9920853
[TBL] [Abstract][Full Text] [Related]
3. Plasma cell leukemia: Clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases.
Alghasham N; Alnounou R; Alzahrani H; Alsharif F
Hematol Oncol Stem Cell Ther; 2015 Jun; 8(2):71-7. PubMed ID: 25929729
[TBL] [Abstract][Full Text] [Related]
4. Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation.
Johnson MR; Del Carpio-Jayo D; Lin P; Giralt S; Anderlini P; Champlin RE; Khouri IF; Vadhan-Raj S; Medeiros LJ; Bueso-Ramos CE
Ann Diagn Pathol; 2006 Oct; 10(5):263-8. PubMed ID: 16979517
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell leukemia: a retrospective study of 10 cases.
Agarwal AD; Brahmbhatt BS; Parikh BP; Shah MJ
Indian J Cancer; 2014; 51(1):18-9. PubMed ID: 24947090
[TBL] [Abstract][Full Text] [Related]
6. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
[TBL] [Abstract][Full Text] [Related]
7. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia.
Bladé J; Kyle RA
Hematol Oncol Clin North Am; 1999 Dec; 13(6):1259-72. PubMed ID: 10626149
[TBL] [Abstract][Full Text] [Related]
8. Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features.
Robak T; Urbańska-Rys H; Robak E; Bartkowiak J; Strzelecka B; Biernat W; Kordek R
Leuk Lymphoma; 2002 May; 43(5):1067-73. PubMed ID: 12148888
[TBL] [Abstract][Full Text] [Related]
9. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
10. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia.
Cha CH; Park CJ; Huh JR; Chi HS; Suh CW; Kang YK
Acta Haematol; 2007; 118(3):178-82. PubMed ID: 17934254
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
12. Plasma cell leukemia: Single institution experience.
Babu KG; Jacob LA; Agarwal A; Lakshmaiah KC; Lokanatha D; Suresh Babu MC; Rajeev LK; Lokesh KN; Rudresha AH
Indian J Cancer; 2016; 53(4):619-620. PubMed ID: 28485366
[TBL] [Abstract][Full Text] [Related]
13. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
Bezdekova R; Jelinek T; Kralova R; Stork M; Polackova P; Vsianska P; Brozova L; Jarkovsky J; Almasi M; Boichuk I; Knechtova Z; Penka M; Pour L; Sevcikova S; Hajek R; Rihova L
Br J Haematol; 2021 Oct; 195(1):95-107. PubMed ID: 34500493
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell leukemia: concepts and management.
Liedtke M; Medeiros BC
Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell leukemia.
Albarracin F; Fonseca R
Blood Rev; 2011 May; 25(3):107-12. PubMed ID: 21295388
[TBL] [Abstract][Full Text] [Related]
16. Primary plasma cell leukaemia: a report of 18 cases.
Costello R; Sainty D; Bouabdallah R; Fermand JP; Delmer A; Diviné M; Marolleau JP; Gastaut JA; Olive D; Rousselot P; Chaïbi P
Leuk Res; 2001 Feb; 25(2):103-7. PubMed ID: 11166824
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemia.
Shimazaki C; Gotoh H; Ashihara E; Oku N; Inaba T; Murakami S; Itoh K; Ura Y; Nakagawa M; Fujita N
Am J Hematol; 1992 Mar; 39(3):159-62. PubMed ID: 1546712
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
Colomo L; López-Guillermo A; Perales M; Rives S; Martínez A; Bosch F; Colomer D; Falini B; Montserrat E; Campo E
Blood; 2003 Jan; 101(1):78-84. PubMed ID: 12393466
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China.
Peijing Q; Yan X; Yafei W; Dehui Z; Zengjun L; Junyuan Q; Yaozhong Z; Lugui Q
Acta Haematol; 2009; 121(1):47-51. PubMed ID: 19339770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
